

## TECH CENTER 1600/2900

RECEIVED
APR 0 8 2002

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Norman Nashed.

Examiner: S. Qazi

Serial No.: 09/619,493

Group Art Unit: 1616

Filed: July 19, 2000

Title: THERAPEUTIC GESTAGENS FOR THE TREATMENT OF PREMENSTRUAL

DYSPHORIC DISORDER

## **REPLY**

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

This Reply is responsive to the Office Action mailed October 3, 2001 in the above-referenced application.

## **REMARKS**

The two obviousness rejections (over two Abstracts - Neumann, and Guenther et al.) are traversed. Although the two Abstracts may disclose using a combination of an estrogen and a progestagen to treat various disorders, neither Abstract discloses or suggests that such a combination can be used to treat PMDD (premenstrual dysphoric disorder), a distinctly classified condition. The instant claims are distinguishable from the references, at least because a different class of patient is treated from the patients disclosed by the references. Neither of the references,

SCH 1686 C1